13F Holdings
中文EN

BHST BIOHARVEST SCIENCES INC. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1723464 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY37.0%
TTM net income YoY13.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin59.3%
Operating margin-16.2%
Net margin-32.3%
FCF margin-27.8%
EBITDA margin-11.4%

Returns

ROE-83.2%
ROA-30.6%
ROIC (approx.)-646.3%
Asset turnover0.95x

Leverage & solvency

Liabilities / assets46.6%
Debt / equity0.00x
Current ratio3.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue6.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$34.51M$25.19M$12.67M
Cost of revenue$14.03M$11.25M$7.04M
Gross profit$20.48M$13.94M$5.63M
R&D expense$5.31M$4.80M$3.37M
SG&A expense$4.93M$4.40M$4.48M
Operating income-$5.58M-$6.99M-$9.97M
Pretax income-$11.06M-$12.90M-$12.56M
Income tax-$76,000-$8,000$0
Net income-$11.13M-$12.91M-$12.56M
EBITDA-$3.95M-$5.74M-$9.13M
EPS (basic)-0.60-0.80-0.93
EPS (diluted)———
Balance sheet
Cash & equivalents$23.02M$2.39M$5.36M
Receivables$1.98M$1.12M$808,000
Inventory$4.56M$3.65M$2.47M
Current assets$30.50M$7.86M$9.05M
PP&E, netmay include right-of-use assets (IFRS)$8.33M$7.75M$3.93M
Total assets$47.66M$25.00M$15.00M
Current liabilities$7.68M$14.26M$26.47M
Short-term debt$149,000$3.90M$0
Total liabilities$22.22M$23.67M$29.86M
Shareholders' equity$25.45M$1.33M-$14.85M
Cash flow statement
Operating cash flow-$7.23M-$6.68M-$8.52M
Capital expenditure$2.35M$2.83M$1.47M
Free cash flow-$9.58M-$9.52M-$10.00M
Investing cash flow-$2.37M-$3.03M-$1.47M
Financing cash flow$30.19M$6.78M$13.56M
Depreciation & amortization$1.62M$1.25M$840,000
Stock-based compensation—$601,000$563,000

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.